Post Earnings Update: Idenix Pharmaceuticals Has Sunk 7.6% Lower in Past Week (IDIX)
Comtex SmarTrend(R) - Mon May 12, 12:06PM CDT
When Idenix Pharmaceuticals (NASDAQ:IDIX) reported earnings 11 days ago on May 1st, 2014, analysts, on average, expected the company to report a loss of $0.20 on sales of $558.0 thousand. The company actually reported a loss of $0.24 per share on sales of $0.0 thousand, missing EPS estimates by $0.04 and missing revenue estimates by $0.6 million. Shares of Idenix Pharmaceuticals have slipped from $5.54 to $5.12, representing a loss of 7.6%, since the company reported earnings 11 days ago.
Biotech Stocks on our Radar -- Research on ImmunoGen, Idenix Pharma, Repligen, and Vanda Pharma
PR Newswire - Fri May 09, 12:22PM CDT
On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the session at 16,550.97, up 0.20% and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 664.48, down 0.53%, while the index has gained 0.78% in the previous one month. Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Repligen Corp. (NASDAQ: RGEN) and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free technical research on IMGN, IDIX, RGEN and VNDA can be downloaded upon signing up at:
Idenix Pharmaceuticals Down 17.0% Since SmarTrend Downtrend Call (IDIX)
Comtex SmarTrend(R) - Thu May 08, 11:06AM CDT
SmarTrend identified a Downtrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on March 26th, 2014 at $6.30. In approximately 1 month, Idenix Pharmaceuticals has returned 16.98% as of today's recent price of $5.23.
Idenix's Q1 Loss Widens - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 9:11AM CDT
Idenix's (IDIX) loss widens in the first quarter of 2014.
Idenix Pharmaceuticals Reports First Quarter 2014 Financial Results and HCV Pipeline Review
GlobeNewswire - Thu May 01, 3:11PM CDT
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the first quarter ended March 31, 2014.
Shares of IDIX Down 15.5% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu May 01, 9:57AM CDT
SmarTrend identified a Downtrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on March 26th, 2014 at $6.30. In approximately 1 month, Idenix Pharmaceuticals has returned 15.48% as of today's recent price of $5.33.
Idenix Pharmaceuticals to Present at Three Upcoming Healthcare Conferences
GlobeNewswire - Wed Apr 30, 7:14AM CDT
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), announced today that Idenix management will host a fireside chat at the Deutsche Bank Securities 39 Annual Health Care Conference on Wednesday, May 7, 2014 at 3:30 p.m. ET at the InterContinental in Boston, MA. Idenix management will also present a corporate overview at the Bank of America Merrill Lynch 2014 Health Care Conference on Tuesday, May 13, 2014 at 8:00 a.m. PT at the Encore at the Wynn in Las Vegas, NV, and at the 2014 UBS Global Healthcare Conference on Monday, May 19, 2014 at 8:00 a.m. ET at the Sheraton New York Hotel in New York, NY.
Downtrend Call Working As Idenix Pharmaceuticals Stock Falls 12.5% (IDIX)
Comtex SmarTrend(R) - Thu Apr 24, 9:22AM CDT
SmarTrend identified a Downtrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on March 26th, 2014 at $6.30. In approximately 4 weeks, Idenix Pharmaceuticals has returned 12.54% as of today's recent price of $5.51.
Idenix Pharmaceuticals Has Returned 11.7% Since SmarTrend Recommendation (IDIX)
Comtex SmarTrend(R) - Fri Apr 11, 11:17AM CDT
SmarTrend identified a Downtrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on March 26th, 2014 at $6.30. In approximately 2 weeks, Idenix Pharmaceuticals has returned 11.75% as of today's recent price of $5.56.
Pipeline Update from Idenix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 3:55PM CDT
Idenix's nucleotide polymerase inhibitor candidate, IDX21437, showed potent antiviral activity in patients suffering from hepatitis C virus (HCV) infection.
Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma
PR Newswire - Tue Apr 08, 12:15PM CDT
The US markets saw a negative sentiment on Monday, April 07, 2014, with the NASDAQ Composite closing at 4,079.75, down 1.16%, the Dow Jones Industrial Average ending the session at 16,245.87, down 1.02%, and the S&P 500 edging 1.08% lower to finish the trading session at 1,845.04. The losses were broad based as nine out of 10 sectors ended the session in negative. A number of stocks saw large movements, including Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Agios Pharmaceuticals Inc. (NASDAQ: AGIO), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX). Free technical research on PPHM, AGIO, IDIX and LXRX can be downloaded upon signing up at:
Idenix Pharmaceuticals (IDIX) Jumps: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:51AM CDT
Idenix Pharmaceuticals Inc. was a big mover last session, as its shares rose over 12% on the day.
Why Idenix Pharmaceuticals, B&G Foods, and Petrobras Rose Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Apr 07, 7:02PM CDT
Last week's memories of near-record closes for the Dow Jones Industrials faded further into the background Monday, as the Dow posted a decline of more than 1% amid growing concerns about the market's valuation. Even though more volatile sectors of...
MannKind vs. Idenix: Better Biotech Buy
David Williamson, The Motley Fool - Motley Fool - Mon Apr 07, 6:17PM CDT
In this video after a big day in the biotech sector, Motley Fool health-care analyst David Williamson takes investors through today's big winner and loser. Idenix is the winner for the day, up 10% after posting solid results in a...
Nasdaq stocks posting largest percentage increases
AP - Mon Apr 07, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Idenix Pharmaceuticals Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 07, 12:12PM CDT
What: Shares of Idenix Pharmaceuticals , a clinical-stage biopharmaceutical company developing therapies to treat human viral diseases, jumped as much as 14% after reporting data and updating the progress of its nucleotide prodrug inhibitor...
Idenix Announces Promising Clinical Data and Continued Progress in Nucleotide Prodrug Development Programs for the Treatment of Hepatitis C
GlobeNewswire - Mon Apr 07, 6:06AM CDT
-- Idenix Reports Positive Proof-of-Concept Data for Lead Nucleotide Prodrug, IDX21437
52.5% Return Seen to Date on SmarTrend Idenix Pharmaceuticals Call (IDIX)
Comtex SmarTrend(R) - Tue Mar 25, 9:14AM CDT
SmarTrend identified an Uptrend for Idenix Pharmaceuticals (NASDAQ:IDIX) on November 4th, 2013 at $4.43. In approximately 5 months, Idenix Pharmaceuticals has returned 52.54% as of today's recent price of $6.75.
Idenix Announces Nucleotide Prodrug (IDX21437) and NS5A Inhibitor (Samatasvir) Poster Presentations at 49th Annual Meeting of the European Association for the Study of the Liver
GlobeNewswire - Mon Mar 24, 7:05AM CDT
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced three poster presentations featuring clinical and preclinical data for the Company's nucleotide prodrug, IDX21437, and for samatasvir, Idenix's once-daily pan-genotypic NS5A inhibitor, at The International Liver Congress(TM) 2014, the 49th annual meeting of the European Association for the Study of the Liver (EASL), taking place in London, April 9-13, 2014. Full abstracts can now be viewed at the EASL Congress website.